Join
Live feed
·
PRReleasevia Quantisnow
Satsuma Pharmaceuticals Inc. logo

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

ByQuantisnow·Wall Street's wire, on your screen.
STSA· Satsuma Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STSA (Satsuma Pharmaceuticals Inc.) and more on Quantisnow.